Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MixedRadiationC57BL/6 primary; BALB/c confirmatory survival; Lgr5-EGFP-IRES-creERT2 for organoid and intestinal stem cell studiesn = Three or more mice per group for immunohistochemistry; n pe…Subcutaneous injection2.5 mg/kg identified as optimal; dose-response tested at 0,…First dose within 1 hour after radiation exposure (day 0), so a post-exposure m…
Model: Radiation-induced acute gastrointestinal syndrome: whole-body irradiation at 8 to 14 Gy using a cobalt-60 irradiator, and abdominal X-ray irradiation at 14 Gy; survival observed for 30 days. In vitro 6 Gy for organoids and 10 Gy for IEC-6 cells
Subcutaneous Me6TREN at 2.5 mg/kg on days 0, 3, 6, 9 and 12 improved survival after 8 Gy whole-body irradiation (40% versus 0% with PBS), extended median survival after 14 Gy from 5 to 10 days, and raised survival after 14 Gy abdominal irradiation to 80% versus 15%, with increased crypt and villus…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.